



PRESS RELEASE

RPG Life Sciences to acquire 7 prescription brands from Sun Pharma

- **Q1'FY17 revenue up 28%; profit at Rs 9.87 crore**
- **Announces collaboration with US-based Biophore**

Mumbai, July 27, 2016: RPG Life Sciences Ltd, part of the Rs 21,000-crore RPG Group, engaged in manufacturing and marketing of pharmaceutical products, today signed an agreement to acquire seven prescription brands from Sun Pharmaceutical Industries Limited together with its subsidiaries.

The move is in line with the company's strategy to focus on formulations business. The acquired brands are primarily in respiratory and urology segments. In addition to this, three products will compliment the company's existing range.

Talking about the development, Mr. CT Renganathan, Managing Director, RPG Life Sciences said, "Historically, the company has invested in in-licensing products. This is the first time that we have made a brand acquisition. We believe these brands have a huge potential to grow and are a perfect fit to our current portfolio and in line with our long-term growth strategy."

This deal is subject to receipt of Competition Commission of India's (CCI) approval.

Financial Results:

Meanwhile, the company also announced the unaudited financial results for the quarter ended June 30, 2016, posting a 28% surge in net sales that stood at Rs 85.23 crore as against Rs 66.5 crore for the corresponding quarter last year. PAT grew Rs 9.87 crore as against Rs 2.14 crore and EBITDA for the quarter surged to Rs 12.95 crore as against Rs 5.63 crore in the corresponding quarter of the previous year, a growth of 130%. Margins grew by 743 bps to stand at 15.9%.

"This quarter's performance has been driven by robust growth in international business. Due to regulatory reasons, our Canadian customer advanced their requirements to the first half of the financial year by giving orders during the current quarter resulting in higher sales. Also, our ROW sales had higher pickup from our customers in Myanmar and Mauritius. Overall, we have started the year on a good note and we hope to maintain consistent growth on quarter on quarter basis," commented Mr. Renganathan.

Joins hands with Biophore:

Furthermore, the company also announced its collaboration with US-based Biophore, to develop, file and commercialize products specifically targeting the US market. As a part of this strategic tie-up, Biophore will develop, manufacture and file finished dosage formulations (DMF) for the API whereas RPGLS shall develop, manufacture, file and commercialize these products from its manufacturing facility for regulated markets.

RPG Life Sciences will be entering into a collaboration with Biophore for the development of niche products for the US market. To begin with, the company will start with four projects which shall be achieved in two phases comprising of two products each. The company will own the ANDA

for these products in the US market while exploring the potential for these products in the other regulated markets with Biophore.

“This alliance is in accordance with our target to enter the US market in the next 24 to 36 months from now. We desire to have our own set up in the region and shall adopt strategic partnership models for this market for product development and marketing focused for US market. We will explore and go for First to File, First Few to File, NCE-1 product opportunities for US market along with niche formulations with limited competition,” pointed out Mr. Renganathan.

About Biophore (www.biophore.com):

Biophore a global API company focuses on developing molecules with complex chemistry and niche APIs for generic industry. Biophore’s product portfolio includes generic APIs that are often complex, difficult to characterize, peptides, macromolecular complexes, co-crystals, steroidal APIs, diagnostic and contrast MRI media. Biophore’s portfolio is broad and spread across a diverse range of therapeutic segments. Biophore is amongst the top suppliers of APIs to the US market. With over 60 patents filed in the areas of novel processes and polymorphs & 40 DMFs filed with US FDA and EU authorities, Biophore aims to become the most trusted API supplier in the world.

About RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics, synthetic and fermentation APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

Mumbai head-quartered RPG Enterprises is one of India's largest industrial conglomerates. With over 15 companies in its fold, the group has a strong presence across core business sectors such as Infrastructure, Tyre, IT and Specialty. Established in 1979, RPG Enterprises is one of India’s fastest growing business groups with a turnover in excess of Rs 21,000 crore.

Media Contact:

Chikita Kukreja – 9820191347 – chikita@rpg.in